[Treatment for multiple myeloma: current status and future strategy in Japan].
Shinsuke
S
Iida
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007564:Japan; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use; D013997:Time Factors; D014182:Transplantation, Autologous
D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007155:Immunologic Factors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan